Science and Research

[Updated Recommendation for Treatment of Metastatic Non-Small Cell Lung Cancer]

Lung cancer accounts for the leading cause of cancer deaths in Germany and is characterized by early metastasis formation. The majority of patients with non-small cell lung cancer (NSCLC) will receive systemic therapy for treatment of their disease. Importantly together with the identification of targetable oncogenic alterations, systemic treatment of NSCLC has dramatically changed in recent years with the implementation of various new agents such as tyrosine kinase inhibitors and immune modulating drugs. However, these new therapeutic options also challenge the treating physician since molecular, histologic, and clinical factors need to be considered for the clinical decisionmaking. Moreover, supportive therapy including bronchoscopic therapy has evolved. The following therapy recommendations will summarize the up-to date treatment strategies for metastatic NSCLC.

  • Reinmuth, N.
  • Groschel, A.
  • Schumann, C.
  • Sebastian, M.
  • Wiewrodt, R.
  • Reck, M.

Keywords

  • Aged
  • Antineoplastic Agents/therapeutic use
  • Bronchoscopy
  • Carcinoma, Non-Small-Cell Lung/epidemiology/pathology/*therapy
  • Clinical Decision-Making
  • Clinical Trials as Topic
  • Cross-Sectional Studies
  • Germany
  • Humans
  • Immunomodulation
  • Lung Neoplasms/epidemiology/pathology/*therapy
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Palliative Care
  • Protein Kinase Inhibitors/therapeutic use
  • Novartis, MSD, BMS, Boehringer-Ingelheim, Astra-Zeneca, Pfizer.A. Groschel:
  • Honorare fur Vortrage von Roche, BMS.C. Schumann: Honorare fur Vortrage,
  • Beratungen und Kongressreisen: Pfizer, Roche, BMS, Astra, Boehringer, Lilly.M.
  • Sebastian: Honorare fur Vortrage und Beratungstatigkeiten (Advisory Board) fur
  • AstraZeneca, BMS, Boehringer-Ingelheim, Celgene, MSD, Novartis, Pfizer, Roche,
  • Merck, Lilly, Takeda.R. Wiewrodt: Honorare fur Beratungen und Vortrage von
  • Astra-Zeneca, Bayer, BMS, Boehringer-Ingelheim, Celgene, CSL, GSK, Hoffmann-La
  • Roche, Lilly, MSD, Novartis, Pfizer.M. Reck: Honorare fur Vortrage und
  • Beratungstatigkeiten (Advisory Board) fur AstraZeneca, BMS, Boehringer-Ingelheim,
  • Celgene, MSD, Novartis, Pfizer, Roche, Merck.
Publication details
DOI: 10.1055/s-0043-118904
Journal: Pneumologie (Stuttgart, Germany)
Pages: 138-154 
Number: 2
Work Type: Review
Location: ARCN
Disease Area: LC
Partner / Member: ASK, Ghd
Access-Number: 29270953
See publication on PubMed

DZL Engagements

chevron-down